Search for content, post, videos

WntResearch plans clinical phase 1b study

nils brunner wntresearch källa youtube

The company has submitted an application to the Danish Health Authorities regarding permission to start the Foxy-5 clinical phase 1b study.

“This is a very important milestone for WntResearch. I feel confident that the phase 1b study will provide us with the information needed to optimize conditions for the pivotal clinical phase 2 study. The major difference between the phase 1 and 1b studies and the phase 2 study lies in the recruitment of patients. The phase 1 and 1b studies recruit patients who already have metastatic disease and for whom the treating oncologist has no more routine systemic treatment to offer. On the contrary, the phase 2 study will recruit only newly operated cancer patients with no signs of persistent metastatic lesions. Thus, the phase 2 study will give us the final answer to the anti-metastatic efficacy of Foxy-5,” commented Nils Brünner, CEO of WntResearch.

WntResearch AB develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1, Foxy-5, as well as one candidate drug in preclinical development, Box-5. The company is currently focusing mainly on the development of Foxy-5.

Source: WntResearch